Efficacy
After a median follow-up of 8.4 years, the 5-year PFS for induction cisplatin-capecitabine vs. adjuvant cisplatin-5FU was 78.4% and 61.5% respectively (HR 0.60, p = 0.027) and 5-year OS rate was 83.3% and 71.9% respectively (HR 0.64, p = 0.097) in patients receiving conventional RT.r
Progression-free survival by chemotherapy regimen for patients receiving conventional fractionation radiation therapyr
© Cancer 2020
Overall comparisons regarding chemotherapy regimen and/or sequence (irrespective of RT fractionation) did not show any significant differences on PFS or OS endpoints. However, when adjusted to RT fractionation groups, the 5-year PFS rate for patients receiving induction-concurrent compared to concurrent-adjuvant sequence (regardless of cisplatin-5FU or cisplatin-capecitabine regimen) was 77.6% and 61.5% respectively (HR 0.62, p = 0.015) and the 5-year OS rate was 83.6% and 71.9% (HR 0.63, p = 0.042).
Progression-free survival of induction cisplatin and 5FU or capecitabine vs. adjuvant cisplatin and 5FUr
© Cancer 2020
Overall survival of induction cisplatin and 5FU or capecitabine vs. adjuvant cisplatin and 5FUr
© Cancer 2020